Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 3:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 1,359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FAST alone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALXN2050 in Healthy Adult Participants of Japanese Descent

NCT04952545
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Bioavailability and Food Effect of SACT-1 and Edurant® Tablets in Healthy Adult Volunteers

NCT05358756
View directory record Official record
Conditions
Healthy Subject
Interventions
SACT-1, EDURANT 25Mg Tablet
Drug
Lead sponsor
Aptorum International Limited
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

NCT01149629
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
Droxidopa
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
65 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

NCT03163173
View directory record Official record
Conditions
Healthy Volunteers, Healthy
Interventions
GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348

NCT03703505
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG-348, [13C6]AG-348
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 12, 2018 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence of TTYP01 Tablets in Healthy Adult Subjects

NCT06107205
View directory record Official record
Conditions
Healthy Adult Subjects
Interventions
TTYP01, Radicava, Radicava ORS
Drug
Lead sponsor
Shanghai Auzone Biological Technology Co., Ltd.
Industry
Eligibility
20 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults

NCT05319912
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840 Enteric-coated Tablet, ALXN1840 Non-coated Capsule, Omeprazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 2, 2023 · Synced Oct 24, 2026, 3:57 PM EDT
Recruiting Phase 1 Interventional

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT06789172
View directory record Official record
Conditions
Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions
OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist
Drug · Combination Product · Other
Lead sponsor
Epkin
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Beverly Hills, California • Santa Monica, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBP-9330, Placebo
Drug
Lead sponsor
Camino Pharma, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2024 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Bioequivalence of the 4mg Prototype Mini Nicotine Lozenge to the Reference Product (Nicorette) in Healthy Smokers

NCT03543137
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine Prototype Mini lozenge, Nicorette Mini Lozenge
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2019 · Synced Oct 24, 2026, 3:57 PM EDT
Active, not recruiting Phase 2 Interventional

Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers

NCT05722288
View directory record Official record
Conditions
Localized Prostate Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Rectal Carcinoma, Malignant Solid Neoplasm, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IB Cervical Cancer FIGO 2018, Stage IB2 Cervical Cancer FIGO 2018, Stage II Prostate Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage III Prostate Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IVA Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Informational Intervention, Quality-of-Life Assessment, Questionnaire Administration, Short-Term Fasting
Procedure · Other · Behavioral
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of 100 mg Cilostazol Tablets Under Fasting Conditions

NCT00602173
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Cilostazol
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 24, 2026, 3:57 PM EDT
Not listed Not applicable Interventional

Preventing OUD in Justice-Involved Youth

NCT04901312
View directory record Official record
Conditions
Substance Use Disorders, Recidivism
Interventions
Adolescent Community Reinforcement Approach, Assertive Continuing Care, Trauma Affect Regulation Guide for Education and Therapy, Motivational Interviewing, Opioid Education Workbook
Behavioral · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
15 Years to 25 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Olympia, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fasting Conditions.

NCT01131897
View directory record Official record
Conditions
Healthy
Interventions
Levetiracetam
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 14, 2010 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose PK, Oral Bioavailability and Food Effect Study in Healthy Male Volunteers

NCT03852446
View directory record Official record
Conditions
Healthy
Interventions
Indoximod HCL (F2) tablets, Indoximod base formulation, Placebo
Drug · Other
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects

NCT02039076
View directory record Official record
Conditions
Thrombocytopenia
Interventions
avatrombopag
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 24, 2026, 3:57 PM EDT
Not listed Not applicable Interventional

Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)

NCT06515782
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Med Diet. Investigators would like to see what differences a Mediterranean Diet makes to the status of patients with Multiple Sclerosis.
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

NCT06497517
View directory record Official record
Conditions
Cough
Interventions
GSK5464714- Camlipixant
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2025 · Synced Oct 24, 2026, 3:57 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study of TU2218 Alone and in Combination With Checkpoint Inhibitors in Patients With Advanced Solid Tumors

NCT05204862
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
TU2218, Anti-PD-1 antibody
Drug
Lead sponsor
TiumBio Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Anagrelide Hydrochloride Capsules 1 mg to Agrylin® Capsules 1 mg

NCT00648024
View directory record Official record
Conditions
Healthy
Interventions
Anagrelide Hydrochloride Capsules 1 mg, Agrylin® Capsules 1 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg and Lopressor HCT® Tablets 100/50 mg

NCT00649688
View directory record Official record
Conditions
Healthy
Interventions
Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg, Lopressor HCT® Tablets 100/50 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food and Calcium on Pharmacokinetics of a Single Dose of S-888711 in Healthy Adult Volunteers

NCT03897413
View directory record Official record
Conditions
Healthy Volunteer
Interventions
S-888711, Calcium Antacid
Drug · Dietary Supplement
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 24, 2026, 3:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot BA Study of New LY03005 vs Pristiq

NCT02988024
View directory record Official record
Conditions
Major Depression
Interventions
LY03005, Pristiq
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 24, 2026, 3:57 PM EDT